Acute basophilic leukemia

Summary

Acute basophilic leukemia (MONDO:0019458) is a cancer. A subtype of acute myeloid leukemia by FAB classification — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	acute basophilic leukemia
Mondo ID	MONDO:0019458
EFO	EFO:0003029
MeSH	D015471
Orphanet	86849
DOID	DOID:0080795
ICD-11	1632520399
NCIT	C3164
SNOMED CT	307592006
UMLS	C0023437
MedGen	7314
GARD	0019071
Is cancer (heuristic)	yes

Also known as: basophilic leukaemia · basophilic leukemia · leukaemia basophilic · leukemia basophilic

Disease family

This is a subtype of acute myeloid leukemia by FAB classification. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › acute myeloid leukemia › acute myeloid leukemia by FAB classification › acute basophilic leukemia

Related subtypes (8): acute myeloid leukemia with minimal differentiation, acute myeloblastic leukemia without maturation, myeloid sarcoma, acute erythroid leukemia, acute myelomonocytic leukemia M4, acute megakaryoblastic leukemia, acute panmyelosis with myelofibrosis, acute myeloblastic leukemia with maturation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aldesleukin	Phase 3 (in late-stage trials)
Asparaginase	Phase 3 (in late-stage trials)
Busulfan	Phase 3 (in late-stage trials)
Cytarabine	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Thioguanine	Phase 3 (in late-stage trials)
Valspodar	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.